行情

ARQL

ARQL

ArQule
NASDAQ

实时行情|Nasdaq Last Sale

19.99
-0.21
-1.04%
已收盘, 19:59 12/12 EST
开盘
20.20
昨收
20.20
最高
20.26
最低
19.95
成交量
532.43万
成交额
--
52周最高
20.45
52周最低
2.230
市值
24.13亿
市盈率(TTM)
-58.1274
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARQL 新闻

  • 美国企业债28年来首超家庭负债 这背后有哪些隐患?
  • 新浪财经综合.19分钟前
  • 西方资产:欧洲央行会议点评——“聪明的猫头鹰”
  • 新浪财经-自媒体综合.20分钟前
  • 沪指涨1.78% 特朗普推文引爆美股、人民币汇率飙升
  • 新浪财经.37分钟前
  • 汇丰:预计英国央行将在2020年5月降息25个基点
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
+0.57%
制药与医学研究
+0.73%

热门股票

名称
价格
涨跌幅

ARQL 简况

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
展开

Webull提供ArQule, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。